Intensity Therapeutics, Inc.

Equities

INTS

US45828J1034

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-15 pm EST			5-day change	1st Jan Change
0.4181 ^USD	-1.62%		-3.69%	+1.93%

Jan. 13	Intensity Therapeutics highlights 2025 milestones and outlines 2026 strategic priorities	RE
Dec. 11	Intensity Therapeutics, Inc. to Present Two Posters At the 2025 San Antonio Breast Cancer Symposium	CI

Intensity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025

Published on 08/07/2025 at 04:02 pm EDT

S&P Capital IQ

Intensity Therapeutics, Inc.

-1.62%

Intensity Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2025. For the second quarter, the company reported net loss was USD 2.54 million compared to USD 4.97 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to USD 0.36 a year ago.
For the six months, net loss was USD 5.88 million compared to USD 9.57 million a year ago. Basic loss per share from continuing operations was USD 0.35 compared to USD 0.7 a year ago.

Latest news about Intensity Therapeutics, Inc.

Jan. 13	Intensity Therapeutics highlights 2025 milestones and outlines 2026 strategic priorities	RE
Dec. 11	Intensity Therapeutics, Inc. to Present Two Posters At the 2025 San Antonio Breast Cancer Symposium	CI
Dec. 05	Intensity Therapeutics Gets Extension to Regain Nasdaq Minimum Price Requirement	MT
Dec. 05	Intensity Therapeutics granted 180-day extension	RE
Dec. 04	Intensity Therapeutics files for offering of up to $30 million common stock - SEC filing	RE
Dec. 04	Intensity Therapeutics announces two presentations at the upcoming 2025 San Antonio Breast Cancer Symposium	RE
Nov. 06	Intensity Therapeutics Q3 net loss narrows to $2.7 mln	RE
Nov. 06	Intensity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-31	Intensity Therapeutics Prices $4 Million Direct Offering	MT
25-10-31	Intensity Therapeutics, Inc. - Special Call
25-10-30	Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal	CI
25-09-10	Intensity Therapeutics: Invincible-4 TNBC trial update	RE
25-09-10	Intensity Therapeutics, Inc. Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update	CI
25-09-08	Certain Common Stock of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-SEP-2025.	CI
25-09-08	Certain Stock Options of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-SEP-2025.	CI
25-09-08	Certain Warrants of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-SEP-2025.	CI
25-08-07	Intensity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-04	Intensity Therapeutics raises $6.6 million from at the market offering (ATM) stock sales	RE
25-06-30	Intensity Reports Complete Response Rate in Neurological Cancer Models	MT
25-06-30	Intensity Therapeutics, Inc. Announces Int230-6 Achieves 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors	CI
25-06-11	Intensity Therapeutics Prices Public Offering Of 6,675,000 Shares At $0.30 Per Share	RE
25-06-11	Intensity Therapeutics Plans Public Share Offering to Fund Cancer Trial	MT
25-06-11	Intensity Therapeutics Announces Proposed Public Offering Of Common Stock	RE
25-06-11	Intensity Therapeutics Announces Patients Receiving INT230-6 Prior To Start Of Standard-Of-Care May Achieve High Levels Of Tumor Necrosis In Ongoing Randomized Controlled Phase 2 Invincible-4 Study	RE
25-06-11	Intensity Therapeutics, Inc. Announces Patients Receiving Int230-6 Prior to the Start of Standard-Of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 Invincible-4 Study	CI

Chart Intensity Therapeutics, Inc.

Duration

Period

INTS: Dynamic Chart

Company Profile

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. The Company is engaged in developing treatments that address both the regional and systemic nature of a patientâs cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead investigational product candidate, INT230-6, is designed for direct intratumoral injection. Its INT230-6 is primarily comprised of three components: cisplatin, vinblastine sulfate and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of Phase III open-label, randomized study testing the superiority of INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, and Phase II/III clinical study in metastatic triple negative breast cancer.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 11 - Q4 2025 Earnings Release (Projected)

More about the company